In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 201 to 225 of 302

TitleTypeExpected publication date
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]Technology appraisal guidanceTBC
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]Technology appraisal guidanceTBC
Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]Technology appraisal guidanceTBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]Technology appraisal guidanceTBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]Technology appraisal guidanceTBC
Pharmalgen for the treatment of bee and wasp venom allergyTechnology appraisal guidanceTBC
Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]Technology appraisal guidanceTBC
Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269]Technology appraisal guidanceTBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]Technology appraisal guidanceTBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]Technology appraisal guidance
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]Technology appraisal guidance
Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]Technology appraisal guidance
Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]Technology appraisal guidance
Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632]Technology appraisal guidanceTBC
Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]Technology appraisal guidanceTBC
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]Technology appraisal guidance
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines [ID6356]Technology appraisal guidance
Renal cell carcinoma Pathways Pilot [ID6186]Technology appraisal guidanceTBC
Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]Technology appraisal guidanceTBC
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]Technology appraisal guidance
Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]Technology appraisal guidanceTBC
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6436]Technology appraisal guidanceTBC
Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482]Technology appraisal guidance
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women [ID1307]Technology appraisal guidanceTBC
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All